Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high- grade non-Hodgkin lymphoma

Blood

Volumn 96, Issue 1, 2000, Pages 282-287

  Bertolini, Francesco ^a   Fusetti, Lisa ^a   Mancuso, Patrizia ^a   Gobbi, Alberto ^a   Corsini, Chiara ^a   Ferrucci, Pier Francesco ^a   Martinelli, Giovanni ^a   Pruneri, Giancarlo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; ENDOSTATIN; MONOCLONAL ANTIBODY CD20; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

EID: 0034234555     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.1.282     Document Type: Article

References (21)

1. Longo DL. Lymphoma treatment: you have to admit it's getting better. Curr Opin Oncol. 1999;11: 319.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med. 1995;1:27.
3. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150: 815.
4. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398.
5. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064.
6. Bohem T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404.
7. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565.
8. O'Reilly MS, Bohem T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell. 1977;88:277.
9. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730.
10. Hudson WA, Li Q, Le C, Kersey JH. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia. 1998;12:2029.
11. Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human cell engraftment. Stem Cells. 1998;16:166.
12. Philpott NJ, Turner AJC, Scopes J, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood. 1996;87:2244.
13. Thomas DA, Aguayo A, Giles FJ, et al. Thalidomide anti-angiogenesis therapy in Philadelphia-negative myeloproliferative disorders and myelofibrosis [abstract]. Blood. 1999;94:702a.
14. Raza A, Lisak L, Andrews C, et al. Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes [abstract]. Blood. 1999;94: 661a.
15. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol. 1999;106: 504.
16. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90:3167.
17. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728.
18. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic-fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood. 1999;94:3334.
19. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR, Fidler IJ. Organ-site dependent expression of b-FGF in human renal cell carcinoma cells. Am J Pathol. 1994;145:365.
20. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997;349(suppl II):13.
21. Fortier AH, Fogler WE, Tomszewski JE, et al. Recombinant human endostatin protein in cynomolgus monkey produces no toxicological effects following iv administration for 28 consecutive days [abstract]. Clin Cancer Res. 1999;5:3813s.